ReNeuron agrees to move for $19M incentive deal

The Welsh and Sir Chris Evans' life sciences fund have bought themselves an addition to the regional biotech community. The stem cell biotech ReNeuron says it will relocate to South Wales after grabbing a $7.5 million investment from the Wales Life Sciences Investment Fund along with about $12 million in grants from the Welsh government. "This transaction represents the sort of exciting and innovative deal and investment that will become the hallmark of this Arthurian investment strategy for Wales," said Evans, a biotech investor who helped orchestrate the hub strategy. Wales may be swimming against the tide, though, as the industry concentrates around Cambridge, Oxford and London. Story

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.